瑞格列奈对2型糖尿病患者C反应蛋白影响的双盲随机平行对照研究

【目的】观察瑞格列奈治疗2型糖尿病（T2DM）前后血清高敏C反应蛋白（hsCRP）的变化。【方法】采用随机、双盲、安慰剂平行对照方法将142例已合用磺脲类和双胍类药物的T2DM患者随机分至瑞格列奈组及安慰剂对照组，进行为期12周的临床观察。【结果】瑞格列奈组与基线比较FPG、2hPG、HbA1c、胰岛素抵抗指数、hsCRP均明显下降（P均〈0．05）。安慰剂组的HbA1c明显下降（P〈0．05），其他指标均无显著变化。瑞格列奈治疗后患者hsCRP水平明显下降（P〈0．01），而安慰剂组无改变。餐后血糖变化（P〈0．01）及空腹血糖水平的变化（P〈0．01）与hsCRP变化相关。【结论】瑞格列奈治疗T2DM，除能改善胰岛素抵抗，降低血糖，还有明显的抗炎症作用，使hsCRP水平下降。

Effect of Repaglinide on Serum High Sensitivity C-reactive Protein in Patients with Type 2 Diabetes Mellitus

Objective] To observe the change of serum high sensitivity C-reactive protein （hsCRP） in patients with type 2 diabetes after treatment with repaglinide. Methods]A 12-week randomized, double-blind and placebo controlled study was performed to compare the effects of placebo and repaglinide in 142 type 2 diabetic patients who had received metformin and sul- fonylureas treatment. Results] A significant reduction in glycosylated hemoglobin （HbAlc） was observed during treatment with placebo （ P 〈0. 05）, and other indexes had no significant change in placebo group. Fasting plasma glucose, postprandial plasma glucose, HbAlc and hsCRP were all reduced significantly in repaglinide group. A significant reduction in hsCRP level was observed during treatment with repaglinide （ P 〈0. 01）. In the placebo-treated patients, the hsCRP level had no significant change. The overall effect of repaglinide on serum hsCRP was associated with the changes in postprandial plasma glucose （ P 〈0. 01） and fasting plasma glucose （ P 〈0.01）. Conclusion] Repaglinide can reduce plasma glucose and hsCRP in patients with type 2 diabetes, which suggests that repaglinide possesses anti-inflammatory properties.